Publications by authors named "R Hamatake"

Claim this Profile
T
Therapeutic vaccine BRII-179 restores HBV-specific immune responses in patients with chronic HBV in a phase Ib/IIa study.
Haiyan Ma, Tien Huey Lim, Apinya Leerapun, Martin Weltman, Jidong Jia, Robert Hamatake

JHEP Rep· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized clinical trials towards a single-visit cure for chronic hepatitis C: Oral GSK2878175 and injectable RG-101 in chronic hepatitis C patients and long-acting injectable GSK2878175 in healthy participants.
Yanli Deng, Fiona Campbell, Kelong Han, Dickens Theodore, Mark Deeg, Robert Hamatake

J Viral Hepat· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
GSK2818713, a Novel Biphenylene Scaffold-Based Hepatitis C NS5A Replication Complex Inhibitor with Broad Genotype Coverage.
Wieslaw M Kazmierski, Sam Baskaran, Jill T Walker, Nagaraju Miriyala, Ramu Meesala, Robert Hamatake

J Med Chem· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Randomized, Double-Blind, Placebo-Controlled, First-Time-in-Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of GSK3389404 in Healthy Subjects.
Kelong Han, Jennifer Cremer, Robert Elston, Stuart Oliver, Sharon Baptiste-Brown, Robert Hamatake

Clin Pharmacol Drug Dev· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
GSK2878175, a pan-genotypic non-nucleoside NS5B polymerase inhibitor, in healthy and treatment-naïve chronic hepatitis C subjects.
S D Gardner, J Kim, S Baptiste-Brown, V Lopez, R Hamatake

J Viral Hepat· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis